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Introduction: The clinical role of Leclercia adecarboxylata as an opportunistic pathogen in the context of human infections have been 
highlighted by multiple published case reports, describing these bacteria as novel or emerging pathogens. 
Methodology: The study included L. adecarboxylata isolates and laboratory data collected, corresponding to a 13-year time period (between 1 
January 2005 and 31 December 2017). Presumptively identified L. adecarboxylata isolates were re-identified using VITEK 2 Compact ID/AST 
and MALDI-TOF MS analysis. 
Results: n = 34 isolates were verified by VITEK 2 system and MALDI-TOF. The fosfomycin-agar and CPS Elite agar were effective in the 
phenotypic differentiation of the isolates. N = 18 (52.9%) of L. adecarboxylata was considered as clinically significant pathogens (based on 
the clinical signs and symptoms), while n = 16 (47.1%) were considered as contaminants. These pathogens were isolated from wound/abscess 
samples (n = 9), urine samples (n = 6) and blood cultures (n = 3). 31 out of 34 isolates (91.2%) were pan-sensitive (i.e. wild type) to the tested 
antibiotics. The median age of affected patients was 57 years (range: 12-80 years), 11 out of 18 patients (61.1%) presented with underlying 
immunosuppression at the time of isolation. 
Conclusions: Based on the finding of this study, the actual (published) frequency of L. adecarboxylata infections needs to be re-evaluated as 
the risk of misidentification (and reporting the isolate as a pan-sensitive Escherichia coli) is high. Additional reporting of cases, both from a 
microbiological and clinical standpoint, could help clinicians develop a better understanding of the potential of this organism as a pathogen. 
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Introduction 
Leclercia adecarboxylata is a Gram-negative, 
oxidase-negative, motile (with peritrichous flagella) 
facultatice anaerobic rod, belonging to the 
Enterobacterales order (based on Adeolu et al. 2016) 
[1,2]. L. adecarboxylata was first isolated from 
drinking water by Leclerc in 1962 as Escherichia 
adecarboxylata (or ’Enteric group 41’, however, based 
on the protein electrophoretic and nucleic acid-based 
analyses (G+C content of these bacteria is between 52-
54%) of Tamura, this species was reassigned and 
renamed in 1986 [3,4]. Since then, this species has been 
detected from various natural environments (natural 
surface waters, soil, from the surface of plants), animal 
sources and food [5]. The clinical relevance of L. 
adecarboxylata in human infections has not been well 
established [6]. Before the 1990s, this species was 
mostly considered as a contaminant or a bystander, if 
isolated together with a significant pathogen [7]. The 
clinical role of L. adecarboxylata as an opportunistic 
pathogen in the context of human infections have been 
highlighted by multiple published case reports, 
describing these bacteria as novel or “emerging” 
pathogens [8]. L. adecarboxylata was principally 
implicated in infections of immunocompromised, 
severely debilitated patients (the majority of case 
reports/series atest to this), however, in the last several 
years, reports of L. adecarboxylata infections in 
immunocompetent patients, associated with trauma or 
cuts, in addition to the overuse of non-steroidal anti-
inflammatory drugs (NSAIDs) and proton pump-
inhibitors (PPIs) [9-11]. The isolation frequency of 
these microorganisms is very low (the true 
epidemiology of infections is unknown), and it is most 
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frequently detected as a member of a polymicrobial 
flora; this pathogen has been isolated from blood, urine, 
faeces, sputum, wound secretions, pus, abscesses, 
synovial fluid, cerebrospinal fluid and peritoneal fluid 
[6,12,13]. 
The biochemical profile of L. adecarboxylata is 
very similar to a prevalent member of the 
Enterobacterales order, E. coli [14]. Therefore, some 
studies postulate that the incidence of L. 
adecarboxylata infections is most probably 
underestimated and underreported due to 
misidentification of these bacteria by clinical 
microbiology laboratories [6,14]. On classically-used 
culture media relevant in the differentiation of Gram-
negative bacteria (e.g. blood agar, eosine-methylene 
blue [EMB] agar, MacConkey agar), L. adecarboxylata 
colonies resemble those of E. coli, which may 
frequently occur (especially in low-resource settings) if 
the colonies are not investigated further [15]. The 
following biochemical characteristics are used for the 
differentiation of L. adecarboxylata from other 
members of the order: citrate-, lysine-decarboxylase-, 
ornithine-decarboxylase-, H2S-, myo-inositol-, D-
sorbitol-, while lactose+, L-rhamnose+, raffinose+, 
esculin+, indole+, Voges-Proskauer-test+, adonitol+, 
D-mellobiose+ and sucrose+ [16]. However, some 
reports highlight that some isolates of L. 
adecarboxylata are adonitol-negative, while sorbitol-
positive, which is again, characteristic for E. coli [15]. 
The accurate identification of L. adecarboxylata from 
clinical specimens in of utmost importance for 
diagnostic, therapeutic and epidemiological purposes. 
Nevertheless, with the advances in automated 
biochemical-based systems (e.g., BD Crystal, VITEK 2 
ID/AST, MicroScan, molecular biological methods 
(e.g. PCR, 16S rRNA sequencing) and matrix-assisted 
laser desorption/ionization time-of flight mass 
spectrometry (MALDI-TOF MS), the accurate and 
timely identification of various bacterial pathogens is 
more ensured than previously [17,18].  
The aim of our present study is to assess the 
biochemistry, epidemiology and clinical relevance of 
the isolation of L. adecarboxylata from clinical samples 
over a long surveillance period, in addition, to assess 
the antibiotic susceptibilities of these isolates. 
 
Methodology 
Study design and population 
The present retrospective cohort study was 
conducted at the Albert Szent-Györgyi Clinical Center, 
a 1,820-bed primary and tertiary-care teaching hospital 
serving over 600,000 citizens in the Southern Region of 
Hungary [19]. The Institute of Clinical Microbiology 
serves as the primary diagnostic microbiology 
laboratory of the Clinical Center, working 8 hours 7 
days a week, in addition to an on-call system. The study 
included L. adecarboxylata microbiological isolates 
and laboratory data collected, corresponding a 13-year 
time frame (between 1 January 2005 and 31 December 
2017). The utilization of hospital beds was between 62-
71% and the number of nursing days per year was 
ranging between 408,000-477,000 days during the 
study period [19]. Data collection was carried out 
electronically, in the anonymized records of the 
laboratory information system (LIS), corresponding to 
samples positive for L. adecarboxylata isolates, which 
were identified using differential media and phenotypic 
(classical) biochemical methods. All isolates were re-
identified using novel methods (see the Bacterial 
identification section). 
To evaluate the demographic characteristics of 
these infections, patient data was also collected, which 
was limited to sex, age at the sample submission, 
indicators/disease corresponding to sample submission, 
presence/absence of immunosuppression and 
inpatient/outpatient status. Both clinically-significant 
L. adecarboxylata isolates (this was evaluated based on 
consultation with the treating physicians) and 
contaminants were included in the analysis, while 
isolates (and corresponding data) that turned out to be 
different species after re-identification were excluded 
from the study. Only the first isolate per patient was 
included in the study; however, isolates with different 
antibiotic-susceptibility patterns from the same patient 
were considered as different individual isolates [20]. 
 
Bacterial identification, ancillary biochemical testing 
Sample processing in our Institute was carried out 
according to guidelines for routine clinical 
bacteriology, which have been previously described 
[21]. At the time of the sample submission, relevant 
samples were cultured on blood agar, chocolate agar, 
EMB agar, MacConkey agar (bioMérieux, Marcy-
l’Étoile, Lyon, France) and UriSelect agar (in case of 
urine samples; Bio-Rad, Berkeley, CA, USA) plates 
and incubated at 37 °C for 24–48 hours, aerobically. 
Isolates that were identified as “L. adecarboxylata” (n 
= 42) based on presumptive biochemical (tube-based) 
methods and API 20E strips (bioMérieux, Marcy-
l’Étoile, Lyon, France) were stored at -80°C until futher 
analysis. After the surveillance period (2005-2017) had 
ended, all isolates were inoculated onto blood agar, 
EMB agar, MacConkey agar, CHROMID CPS Elite 
agar (bioMérieux, Marcy-l’Étoile, Lyon, France) and 
Gajdács et al. – L. adecarboxylata isolation over 13-years     J Infect Dev Ctries 2020; 14(9):1004-1010. 
1006 
fosfomycin-agar (containing of 32 mg/L fosfomycin 
and 50 mg/mL of glucose-6-phosphate; as most of the 
L. adecarboxylata isolates are fosfomycin-resistant) 
and incubated at 37 °C for 24 hours [14,15]. After the 
incubation period, the phenotypic characteristics of 
Bacterial strains were re-identified using the VITEK 2 
Compact ID/AST automated system (bioMérieux, 
Marcy-l’Étoile, Lyon, France; according to 
manufacturers’ instructions) and MALDI-TOF MS 
analysis. MALDI-TOF measurements were performed 
with direct spotting with HCCA matrix using the 
microFlex LT Biotyper (Bruker Daltonik Gmbh, 
Bremen, Germany) mass spectrometer. The sample 
preparation, methodology, and the technical details of 
the MALDI-TOF MS measurements were described 
elsewhere [22]. The generated protein profile was 
analysed using the MALDI Biotyper RTC 3.1 software 
(Bruker Daltonik Gmbh., Bremen, Germany) and 
compared to the MALDI Biotyper Library 3.1.  
Isolates identified as any species other than L. 
adecarboxylata (n = 8), based on the results of VITEK 
2 and mass spectrometry were excluded from the study 
and further anaylsis. For verification purposes, L. 
adecarboxylata isolates were subjected to manual tube 
tests for the fermentation of adonitol, D-mellobiose, 
sucrose, raffinose, L-rhamnose, myo-inositol and D-
sorbitol [16]. For all tests, colonies after 24 h of 
incubation were used and tests were read after 48 h. E. 
coli ATCC 25922 and L. adecarboxylata ATCC 23375 
were used as quality control strains. 
 
Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed 
using the disk diffusion method and when appropriate, 
E-tests (Liofilchem, Abruzzo, Italy) on Mueller–Hinton 
agar plates for ampicillin, amoxicillin-clavulanic acid, 
piperacillin, cefoxitin, cefuroxime, ceftriaxone, 
cefepime, meropenem, norfloxacin, ciprofloxacin, 
gentamicin, nitrofurantoin and trimethoprim-
sulfamethoxazole based on the European Committee of 
Antimicrobial Susceptibility Testing (EUCAST) 
standard methods [23]. In addition, for the verification 
of discrepant results, VITEK 2 Compact ID/AST 
(bioMérieux, Marcy-l’Étoile, France) was also used. 
Verification of fosfomycin-resistance was performed 
using the fosfomycin-agar, as described previously 
[14,15]. The interpretation of the results was based on 
EUCAST Clinical Breakpoints v.9 for 
Enterobacterales. Staphylococcus aureus ATCC 29213, 
Enterococcus faecalis ATCC 29212, Proteus mirabilis 
ATCC 35659, E. coli ATCC 25922, Klebsiella 
pneumoniae ATCC 700603 and Pseudomonas 




Due to low number of relevant isolates (n = 34), 
only descriptive statistic analysis was performed, 
categorical variables were summarized by frequencies 
and percentages. Continuous data were presented as 
mean ± standard deviation and counts or percentages 
(%) [24]. All statistical analyses were performed using 
Statistical Package for Social Science (SPSS) software 
(IBM SPSS Statistics for Windows 24.0, IBM Corp., 
Armonk, NY, USA). 
 
Ethical considerations 
The study was deemed exempt from ethics review 
by the Institutional Review Board of the University of 
Szeged, and informed consent was not required as data 
anonymity was maintained throughout the study. 
 
Results 
Bacterial identification, ancillary biochemical testing 
Out of the n = 42 isolates identified as “L. 
adecarboxylata” by presumptive biochemical methods, 
n = 34 isolates were verified by VITEK 2 system and 
MALDI-TOF analysis. In case of n = 8 isolates, 
misidentification occurred during the primary isolation 
and identification of the isolates: n = 6 isolates were 
Pantoea agglomerans, while n = 2 were E. coli. The 
aggrement between the identification results of VITEK 
2 and the MALDI-TOF were 100% (42/42). The 
fosfomycin-agar and CPS Elite agar were effective in 
the phenotypic differentiation of the isolates: the former 
detected 33 out of the 34 L. adecarboxylata isolates, 
while the chromogenic agar detected all relevant 
isolates (L. adecarboxylata presented with turquose 
green colonies, while the other isolates produced pink 
colonies). On EMB and MacConkey agar, 29/34 L. 
adecarboxylata isolates showed lactose-fermentation, 
while 3/34 isolates showed hemolysis on blood agar. 
The results of the biochemical tests were the following: 
adonitol-positivity: 33/34, D-mellobiose-positivity: 
34/34, sucrose-positivity: 34/34, raffinose-positivity: 
32/34, L-rhamnose-positivity: 33/34, myo-inositol-
negative: 34/34, D-sorbiotol-negative: 32/34. 
 
Epidemiology of L. adecarboxylata infections, patients 
The complete epidemiology and the patient 
characteristics associated with the isolation of L. 
adecarboxylata as a true pathogen or a contaminant is 
summarized in Table 1. Based on the collected data 
corresponding to the affected patients, in addition to the 
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consultation with the physicians at the time of primary 
isolation, n = 18 (52.9%) of L. adecarboxylata was 
considered as clinically-significant pathogens (based on 
the clinical signs and symptoms), while n=16 (47.1%) 
as contaminants. These pathogens were isolated from 
wound/abscess samples (n=9), urine samples (n = 6) 
and blood cultures (n = 3). Out of these 18 patients, in 
n = 6, L. adecarboxylata was the only isolated 
Table 1. Epidemiology and the patient characteristics associated with the isolation of L. adecarboxylata (2005-2017) 





1 2005 26 M Midstream urine - + Pneumonia - 
 2 2005 46 F Wound secretion - + Erysipelas - 
3 2005 33 M Stool - + Diarrhoea - 
4 2006 50 M Midstream urine + - Urinary tract infection + None 
5 2006 29 F Cervical swab - + Pregnancy (screening) +/- 
 6 2006 9 M Throat swab - + Asthma bronchiale - 
7 2007 63 F Sputum - + Pneumonia - 
8 2008 41 M Aerobic blood culture + - Bacteremia + 
S. epidermidis, S. 
haemolyticus 
9 2008 56 F Wound secretion + - Decubitus ulcers + C. striatum, S. agalactiae, P. aeruginosa 
10 2009 17 M Wound secretion + - Fracture of tarsal bones - None 
11 2009 68 F Wound secretion + - Ulcerated lower limb + 
P. vulgaris, B. fragilis, 
Clostridium spp. 
12 2009 60 M Wound secretion + - Deep cutting injury + K. pneumoniae 
13 2009 30 F Stool - + Sine morbo (screening) -  
14 2010 64 F Aerobic blood culture + - 
Chronic 
pancreatitis + K. pneumoniae 
15 2010 16 M Wound secretion + - Deep cutting injury - E. coli, S. agalactiae, C. acnes 
16 2011 23 F Midstream urine - + Cystitis acuta -  
17 2011 46 M Aerobic blood culture + - Septicaemia + None 
18 2012 67 M Wound secretion + - Soft tissue infection - None 
19 2012 28 M Aerobic blood culture - + Pneumonia -  
20 2012 12 M Abscess + - Deep cutting injury - E. coli, K. oxytoca, C. freundii 
21 2013 17 M Throat swab - + Pharyngitis -  
22 2013 44 F Midstream urine + - End-stage kidney disease - None 
23 2013 55 F Cervical swab - + Aerobic vaginitis -  
24 2014 58 F Midstream urine + - Kidney cyst - K. pneumoniae, E. cloacae 
25 2014 80 F Wound secretion + - Ulcerated lower limb + 
S. aureus, S. haemolyticus, 
C. tertium, P. aeruginosa 
26 2014 77 F Catheter-specimen urine + - 
End-stage kidney 
disease + None 
27 2015 62 M Catheter-specimen urine + - 
End-stage kidney 
disease + S. aureus 
28 2015 35 M Sputum - + Persistent cough - 
 





30 2016 59 M Wound secretion + - Ulcerated lower limb - 
S. putrefaciens, E. cloacae, 
S. agalactiae 
31 2016 52 F Urine (non-specified) + - Pyelonephritis + K. pneumoniae 
32 2017 35 F Stool - + Sine morbo (screening) - 





34 2017 31 F Midstream urine - + Headache - 
M: Male; F: Female; *Co-pathogens were only interpreted in case of clinically-relevant isolates. 
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pathogen, while for the other patients, this pathogen 
was isolated with other co-pathogens, most frequently 
with other members of the gut flora, (e.g. E. coli, K. 
pneumoniae, C. freundii, P. vulgaris) and 
Staphylococcus spp. (Table 1.). The median age of 
patients with clinically-relevant L. adecarboxylata 
infections was 57 years (range: 12-80 years), including 
10 male and 8 female patients (male-to-female ratio: 
1.25). 11 out of 18 patients (61.1%) presented with 
underlying immunosuppression at the time of isolation. 
 
Antibiotic susceptibility of L. adecarboxylata isolates 
Antibiotic susceptibility of the thirty-four L. 
adecarboxylata isolates to the tested antibiotics were 
the following: ampicillin: 32 out of 34, amoxicillin-
clavulanic acid: 34 out of 34, piperacillin: 34 out of 34, 
cefoxitin: 34 out of 34, cefuroxime: 34 out of 34, 
ceftriaxone: 34 out of 34, cefepime: 34 out of 34, 
meropenem: 34 out of 34, norfloxacin: 32 out of 34, 
ciprofloxacin: 34 out of 34, gentamicin: 34 out of 34, 
nitrofurantoin: 32 out of 34 and trimethoprim-
sulfamethoxazole: 31 out of 34. Thus, 31 out of 34 
isolates (91.2%) were pan-sensitive to the tested 
antibiotics. In addition, no differences in susceptibility 




L. adecarboxylata is an uncommon Gram-negative 
bacterium of the Enterobacterales order, sharing many 
biochemical and phenotypical characteristics with other 
members of the order present in the gut flora. In this 
study, cases of isolation (both clinically significant and 
contamination) of L. adecarboxylata were collected 
over a 13-year period in a single institution. The 
isolation frequency of this microorganism was around 
2-3 isolates/year (range: 1-4), thus, it should be 
considered a species with low isolation-frequency. 
Most of the patients were middle-aged and in almost 
two-thirds of the patients, an immunocompromised 
state was verified. More than 90% of species were 
sensitive to all tested antibiotics, significant resistance-
levels were not shown in our Institution.  
Although the number of studies on the clinical role 
of L. adecarboxylata as an opportunistic pathogen is 
increasing, the frequency of reports is currently still too 
small to estimate the route of transmission and 
significance of this pathogen properly [25]. It has been 
suggested that this microorganism has a low pathogenic 
potential and the virulence factors of this species have 
not been adequately characterized [26]. Thus, to cause 
infection, there has to be some kind of breach in the 
anatomical continuity of the tissue, an underlying 
disease or immunosuppression: e.g. compresssion 
ulcers, penetrative injuries, burns, chronic alcoholism, 
diabetes, liver cirrhosis, total parenteral nutrition, 
extensive use of corticosteroids or monoclonal 
antibodies, malignant diseases and anticancer agents, 
kidney failure and/or hemodialysis and presence of 
central venous catheters [6,27]. Of interest, reports of 
diarrhoea and gall bladder infections have also been 
described, which is similar to the role other members of 
gut commensals may play as opportunistic pathogens 
[28-30]. Nonetheless, community-acquired infections 
in immunocompetent individuals and outpatients have 
also been reported (predominantly presenting as UTIs) 
[6]. Recently, a systematic review article summarized 
the published case reports on L. adecarboxylata 
corresponding to the time period between 1991 and 
2017: from 61 publications, 74 patients were affected 
by this pathogen, out of which, only four cases (5.4%) 
were fatal [6]. Most cases (91%) were published from 
North America (n = 26), Europe (n = 22) and Asia (n = 
21), with males being affected twice as much as 
females. Similarly to this study, isolates were the most 
frequently recovered from the blood (25%), urine and 
wound samples (in addition to peritoneal fluid); around 
30% of isolations were monobacterial [6].  
Most of the published reports were in agreement 
and have shown very low levels of resistance in L. 
adecarboxylata isolates for all relevant anti-Gram-
negative antibiotics (apart from benzyl-penicillin), 
which was further verified by our study [6]. The two 
largest laboratory-based studies on the susceptibility of 
these pathogens have been published by Tamura et al. 
in 1986 [4] and by Stock et al. in 2004 [14]. Similarly 
to other published reports, the overwhelming majority 
of isolates were susceptible to tested antibiotics in both 
mentioned studies. Nevertheless, ESBL or AmpC-
producing isolates, resistant isolates to cefotaxime, 
ceftazidime and cefepime were described, in addition to 
an blaNDM-1-producing strain isolated from a male 
patient, suffering an open ankle fracture and crush 
injury to his left foot [31,32]. Comparably to other 
Gram-negative gut bacteria, the emergence and spread 
of multidrug-resistant strains is to expected [33]. 
Due to similar biochemical properties, the risk of 
misidentification between L. adecarboxylata and E. coli 
is significant if only classical biochemical methods are 
used (which is common resource-scarce settings), 
however, the introduction of automated identification 
systems and MALDI-TOF MS play a crucial role in the 
identification of uncommon bacteria and in establishing 
their clinical relevance [34,35]. In low-resource 
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settings, the use of fosfomycin-agar and the strategic 
selection of chromogenic media (e.g. CPS Elite agar) 
that are capable of differentiating L. adecarboxylata 
and E. coli is warranted for their successful isolation 
and identification [14,15]. 
 
Conclusion 
Long-term epidemiological and clinical studies 
(similar to the present report) are required and 
encouraged to ascertain the true prevalence of Leclercia 
infections. Isolation of this pathogen is usually 
monobacterial in immunocompromised patients, while 
in immunocompetent patients, the isolation 
predominantly occurs in a part of a polymicrobial 
culture. To the best of our knowledge, this is the first 
and longest study describing the epidemiology of this 
bacterial pathogen in Hungary. Based on the findings of 
this study, the actual (published) frequency of L. 
adecarboxylata infections needs to be re-evaluated as 
the risk of misidentification (and reporting the isolate as 
a pan-sensitive E. coli) is high. Additional reporting of 
cases, both from a microbiological and clinical 
standpoint, could help clinicians develop a better 
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